A recent phase II study reported the preliminary results of a new drug combination based on a PD1 inhibitor (camrelizumab) with an anti-angiogenesis inhibitor (apatinib) and a DNA topoisomerase I inhibitor (irinotecan) used as second-line treatments in an initial group of 16 ESCC patients with advanced ESCC: 1% CR, 8% PR and 4% SD were observed in these patients [106]. The gene discussed is TOP1; the disease is esophageal squamous cell carcinoma.